



Open End PERLES on the SXI® Bio & Medtech Total Return Index

PERformance Linked to Equity Securities



Final terms

Product Details

Underlying	SXI® Bio & Medtech Total Return Index Valor: 1 781 079 (Reuters: .SBIOM)
Conversion	10 PERLES refer to one <u>SXI® Bio & Medtech Total Return Index</u> $(1 + 0.001)^n$ n = the number of quarters that have passed since Issue Date. For the first time on 31.03.2005. The dates of the 0.10% management fee deduction are: 31 March, 30 June, 30 September and 31 December (in case that any of the dates is not a business day, the next following business day applies).
Initial Index Level	CHF 1'166.89
Issue Price of 1 PERLES	CHF 116.689 (=100.00% of Initial Index Level)

Dates

Issue Date	19 November 2004
Payment Date	01 December 2004
Expiration Date	Open End
Closing date (for Swiss tax purposes):	December 31, for the first time December 31, 2018

General Information

Issuer	UBS AG, Zurich
Lead manager	UBS Investment Bank, Zurich
Issue size	Up to 300'000 Open End PERLES
Settlement	Cash settlement in CHF
Trading	Prices will be available on Reuters UBSDEEW05
Listing	Listing on the SWX (Swiss Exchange) will be applied for SXBIO. First Listing is planned for 29 November 2004.
Lot	Minimum 1 PERLES or a multiple thereof for trading and exercise
Security-Numbers	ISIN: CH0020040397 Valor: 2 004 039

WKN:	tba
Common Code:	tba
Sales Restrictions*	USA, US person, UK (The issue is governed by Swiss law)
Law/Jurisdiction	Swiss / Zurich
Clearing	SIX SIS, Euroclear, Clearstream (registered as intermediated securities with SIX SIS AG, in Switzerland)

Certificates

Certificates are a group of products, which replicate the performance of the underlying. Certificates give the investor the possibility to be diversified with low administrative costs and small investment amounts. The risk of loss is limited to the invested capital.

Issuer Call right	In case the underlying Index is not regarded as a leading benchmark for its underlying equity region any more or in case of legal or regulatory disadvantages of the product Open End PERLES versus comparable investment opportunities, the Issuer has an annual right, on 01 December, for the first time on 01 December, 2006 ("Notice Date") to call the Open End PERLES for early redemption effective 2 years after "Notice Date" has been published to that effect (in case that any of the dates is not a business day, the next following business day applies).
Investor exercise right	In addition to the possibility to sell the Open End PERLES at any time, each Investor has an annual right to exercise his Open End PERLES (notice to be received not later than 10 am on 01 December, Zurich time) for a value of 1/10 of the current Conversion Value at the time of the exercise. The exercise will become effective as of close of business on 01 December of the relevant year (in case that any of the dates is not a business day, the next following business day applies).
Form	Uncertificated Securities
Risk information	Please note that Open End PERLES are investment products which are not governed by Swiss investment fund legislation. Therefore, the investor does not get the specific protection of Swiss Investment Fund Law.

UBS Investment Bank is a business group of UBS AG

This document is for your information only and is not intended to be an offer, or a solicitation of an offer, to buy or sell any financial product. The information and opinions contained in this document have been compiled from or arrived at in good faith from sources believed to be reliable. No representation or warranty, express or implied as to the accuracy or completeness or the information contained herein is made by UBS AG. All opinions expressed herein are subject to change without notice. Futures and Options trading is considered risky, and past performance is not necessarily indicative for future results. Additional note to persons receiving this document in Italy: Any Italian persons receiving this document and requiring further information should contact Giubergia UBS SIM SpA, an affiliate of UBS SA, in Milan.

This document is not intended for distribution into the USA, to U.S. Persons nor for general distribution into the U.K.

Contact:

	UBS AG P.O. Box 8098 Zurich ++41-1-239 68 00* ++41-22-389 50 05* ++41-91-801 95 00* derivatives@ubs.com www.ubs.com/keyinvest
Zurich:	
Geneva:	
Lugano:	
E-Mail:	
Internet:	

Please note that calls made to the numbers marked with an asterisk (*) may be recorded. Should you call one of these numbers, we shall assume that you consent to this business practice.



Terms and Conditions/Prospectus

The terms and conditions and/or the prospectus of the security described in this termsheet can be ordered under Tel. 01/239 47 03, Fax 01/239 21 11 or via E-Mail: swiss-prospectus@ubs.com

*This product may not be sold or offered within the United States or to U.S. persons; the foregoing shall not, however, prohibit sales to U.S. offices of UBS AG

Disclaimer

These securities are not in any way sponsored, endorsed, sold or promoted by the SWX Swiss Exchange and the SWX Swiss Exchange makes no warranty or representation whatsoever, express or implied, either as to the results to be obtained from the use of the SXI[®] Bio & Medtech Total Return Index (the "Index") and/or the figure at which the said Index stands at any particular time on any particular day or otherwise. The Index is compiled and calculated solely by the Swiss Exchange SWX. However, the SWX Swiss Exchange shall not be liable (whether in negligence or otherwise) to any person for any error in the Index and the SWX Swiss Exchange shall not be under any obligation to advise any person of any error therein. SXI[®] Bio & Medtech Total Return Index is a registered trademark of the Swiss Exchange SWX.

Structured Transactions

This information is communicated by UBS AG and/or its affiliates ("UBS"). UBS may from time to time, as principal or agent, have positions in, or may buy or sell, or make a market in any securities, currencies, financial instruments or other assets underlying the transaction to which the termsheet relates. UBS may provide investment banking and other services to and/or have officers who serve as directors of the companies referred to in this term sheet. UBS may pay or receive brokerage or retrocession fees in connection with this transaction. UBS's hedging activities related to this transaction may have an impact on the price of the underlying asset and may affect the likelihood that any relevant barrier is crossed.

Structured transactions are complex and may involve a high risk of loss. Prior to entering into a transaction you should consult with your own legal, regulatory, tax, financial and accounting advisors to the extent you consider it necessary, and make your own investment, hedging and trading decisions (including decisions regarding the suitability of this transaction) based upon your own judgement and advice from those advisers you consider necessary. Save as otherwise expressly agreed, UBS is not acting as your financial adviser or fiduciary in any transaction.

This document is for information purposes only and should not be construed as an offer, recommendation or solicitation to conclude a transaction and should not be treated as giving investment advice. The terms of any investment will be exclusively subject to the detailed provisions, including risk considerations, contained in the Information Memorandum, Prospectus or other issuer documentation for the issue of the Notes (the "Prospectus").

UBS makes no representation or warranty relating to any information herein which is derived from independent sources. This term sheet shall not be copied or reproduced without UBS's prior written permission.

No action has been or will be taken in any jurisdiction that would permit a public offering of the securities described herein, save where explicitly stated in the Prospectus. The securities must be sold in accordance with all applicable selling restrictions in the jurisdictions in which they are sold. Not for distribution in the United States or to U.S. persons.

UBS Investment Bank is a business group of UBS AG

This document is for your information only and is not intended to be an offer, or a solicitation of an offer, to buy or sell any financial product. The information and opinions contained in this document have been compiled from or arrived at in good faith from sources believed to be reliable. No representation or warranty, express or implied as to the accuracy or completeness or the information contained herein is made by UBS AG. All opinions expressed herein are subject to change without notice. Futures and Options trading is considered risky, and past performance is not necessarily indicative for future results. Additional note to persons receiving this document in Italy: Any Italian persons receiving this document and requiring further information should contact Giubergia UBS SIM SpA, an affiliate of UBS SA, in Milan.

This document is not intended for distribution into the USA, to U.S. Persons nor for general distribution into the U.K.

Contact:

	UBS AG
	P.O. Box
	8098 Zurich
Zurich:	++41-1-239 68 00*
Geneva:	++41-22-389 50 05*
Lugano:	++41-91-801 95 00*
E-Mail:	derivatives@ubs.com
Internet:	www.ubs.com/keyinvest

Please note that calls made to the numbers marked with an asterisk (*) may be recorded. Should you call one of these numbers, we shall assume that you consent to this business practice.